N/A
Completed N=20
Proton Therapy for Hodgkin Lymphoma
Source: ClinicalTrials.gov NCT00850200 ↗Enrolled (actual)
20
Serious AEs
0.0%
Results posted
Mar 2014
Primary outcomePrimary: Comparison of Normal Tissue Exposed to Greater Than or Equal to 4 Gy/CGE With Use of Proton Therapy Compared to Both Intensity Modulated Radiotherapy (IMRT) and Conventional Therapy. — 0.161; 0.291; 0.355 percentage of body receiving 4 Gy
Summary
The purpose of this study is to reduce the risk of radiation related side effects and complications by treating with radiation (protons or photons) that exposes less of normal organs to low dose radiation.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Comparison of Normal Tissue Exposed to Greater Than or Equal to 4 Gy/CGE With Use of Proton Therapy Compared to Both Intensity Modulated Radiotherapy (IMRT) and Conventional Therapy. |
0.161; 0.291; 0.355 | — |
| SECONDARY Percentage of Participants Who Survived |
92 | — |
| SECONDARY Percentage of Participants Who Did Not Have Disease Progression |
93 | — |
Eligibility Criteria
Inclusion Criteria
- Confirmed "classic" Hodgkin lymphoma.
- Completed chemotherapy.
Exclusion Criteria
- Prior radiotherapy.
- Prior or concurrent cancer other than non-melanomatous skin cancer.
Data sourced from ClinicalTrials.gov (NCT00850200). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.